Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


A new clinical trial in glioblastoma has been launched based on an innovative immunotherapeutic technique – the CAR T cell which can modify then harness a patient’s own T cells to fight their disease.

Read more

Improved preclinical models are needed in oncology drug development to reduce the high failure rate of new agents. Precision profiling translational platforms are providing these tools, using patient-derived xenograft models to reflect the diversity of the human cancer patient population. Crown Bioscience are currently expanding our diversity and PDX collection through the exciting acquisition of Molecular Response PDX operations.

Read more

New treatments for bladder cancer have been extremely scarce over the past decades. However, the continued rise of checkpoint inhibitor immunotherapies may be providing a new breakthrough for metastatic disease. New developments in the next generation of immuno-oncology models are also up and coming thanks to an extended alliance between Crown Bioscience and the National Resource Center for Mutant Mice.

Read more

Immunotherapy continues to be a hot topic in oncology research this year, with breast cancer vaccines showing promise in early phase clinical studies. Recently published research has shown that a vaccine targeting mammaglobin-A (which is expressed in the majority of breast cancers) is not only well-tolerated, but also shows surprisingly good efficacy in a Phase I study of metastatic disease.

Read more